ABBOTINDIAPharmaceuticals
Abbott India Ltd — Cash Flow Statement
₹25915.00
-1.02%
Abbott India Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 959.24 Cr | 1.16K Cr | 859.28 Cr | 903.59 Cr | — |
| Capital Expenditure | -52.60 Cr | -48.33 Cr | -34.11 Cr | -44.07 Cr | — |
| End Cash Position | 560.59 Cr | 291.74 Cr | 239.67 Cr | 132.71 Cr | — |
| Beginning Cash Position | 291.74 Cr | 239.67 Cr | 132.71 Cr | 218.27 Cr | — |
| Changes In Cash | 268.85 Cr | 52.07 Cr | 106.96 Cr | -85.56 Cr | — |
| Financing Cash Flow | -925.17 Cr | -744.71 Cr | -638.72 Cr | -637.38 Cr | — |
| Interest Paid Cff | -7.10 Cr | -8.87 Cr | -0.49 Cr | -0.70 Cr | — |
| Cash Dividends Paid | -871.22 Cr | -690.60 Cr | -584.36 Cr | -584.36 Cr | — |
| Investing Cash Flow | 182.18 Cr | -416.03 Cr | -147.71 Cr | -395.84 Cr | — |
| Interest Received Cfi | 125.43 Cr | 143.63 Cr | 102.24 Cr | 68.99 Cr | — |
| Net Investment Purchase And Sale | 108.83 Cr | -511.53 Cr | -216.32 Cr | -420.99 Cr | — |
| Sale Of Investment | 3.10K Cr | 4.13K Cr | 5.24K Cr | 2.23K Cr | — |
| Purchase Of Investment | -2.99K Cr | -4.64K Cr | -5.46K Cr | -2.65K Cr | — |
| Net PPE Purchase And Sale | -52.08 Cr | -48.13 Cr | -33.63 Cr | -43.84 Cr | — |
| Sale Of PPE | 0.52 Cr | 0.20 Cr | 0.48 Cr | 0.23 Cr | — |
| Purchase Of PPE | -52.60 Cr | -48.33 Cr | -34.11 Cr | -44.07 Cr | — |
| Operating Cash Flow | 1.01K Cr | 1.21K Cr | 893.39 Cr | 947.66 Cr | — |
| Taxes Refund Paid | -447.06 Cr | -404.47 Cr | -340.86 Cr | -288.99 Cr | — |
| Change In Working Capital | -263.42 Cr | 129.38 Cr | 23.13 Cr | 133.62 Cr | — |
| Change In Other Current Liabilities | 6.66 Cr | 14.69 Cr | -2.65 Cr | 32.77 Cr | — |
| Change In Other Current Assets | 15.02 Cr | -8.84 Cr | 16.95 Cr | -9.56 Cr | — |
| Change In Payable | 40.53 Cr | 95.95 Cr | -1.41 Cr | 119.80 Cr | — |
| Change In Inventory | -262.47 Cr | 29.26 Cr | 38.97 Cr | 29.78 Cr | — |
| Change In Receivables | -63.16 Cr | -1.68 Cr | -28.73 Cr | -39.17 Cr | — |
| Other Non Cash Items | -258.90 Cr | -231.21 Cr | -134.00 Cr | -61.64 Cr | — |
| Stock Based Compensation | 12.31 Cr | 14.07 Cr | 12.22 Cr | 12.93 Cr | — |
| Provisionand Write Offof Assets | 8.56 Cr | 15.99 Cr | -10.15 Cr | 6.82 Cr | — |
| Depreciation And Amortization | 71.80 Cr | 71.17 Cr | 69.97 Cr | 66.10 Cr | — |
| Amortization Cash Flow | 1.98 Cr | 1.24 Cr | 1.28 Cr | 1.19 Cr | — |
| Depreciation | 69.82 Cr | 69.93 Cr | 68.69 Cr | 64.91 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 0.95 Cr | 0.29 Cr | -1.00 Cr | -0.91 Cr | — |
| Gain Loss On Sale Of PPE | 0.65 Cr | -0.16 Cr | 0.26 Cr | 0.00 | — |
| Net Income From Continuing Operations | 1.89K Cr | 1.62K Cr | 1.27K Cr | 1.08K Cr | — |
| Common Stock Dividend Paid | — | -690.60 Cr | -584.36 Cr | -584.36 Cr | -531.23 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Abbott India Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.